Endocrinology Today—June 30, 2026

This week’s Endocrinology update highlights regulatory progress, advancing clinical research, biosimilar launches, safety observations, and diagnostic innovation across diabetes, osteoporosis, and thyroid disease.

In Today’s Newsletter

Dive deeper

🧬 LyGenesis immune tolerance award [1] [US • 25 Jun 2026]

https://www.prnewswire.com/news-releases/lygenesis-receives-award-from-breakthrough-t1d-to-fund-a-research-project-to-induce-immune-tolerance-to-pancreatic-islet-transplantation-302810495.html
Context: LyGenesis (cell therapy platform) received a Breakthrough T1D award for Dr. Eric Lagasse’s thymus program.
Key point: The project supports pre-clinical work to induce immune tolerance after allogeneic pancreatic islet transplantation in Type 1 diabetes.
Implication: Signals pipeline investment and modality expansion.

🩺 Phathom completes VOQUEZNA EoE enrollment [2] [US • 23 Jun 2026]

https://firstwordpharma.com/story/7643148
Context: Phathom enrolled 95 adults at 41 US sites in the randomized, double-blind, placebo-controlled Phase 2 pHalcon-EoE-201 trial.
Key point: VOQUEZNA (vonoprazan) 20 mg once daily is being studied versus placebo for 12 weeks in eosinophilic esophagitis.
Implication: May influence prescriber choice and payer reviews pending full data.

👃 GLP-1s linked to smell and taste impairment [3] [26 Jun 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/glp-1s-linked-smell-taste-impairment-diabetes-patients-2026-06-26/
Context: Reuters reported an electronic health record analysis of nearly 900,000 Type 2 diabetes patients from 2017–2026.
Key point: Long-term GLP-1 use was associated with higher smell and taste disturbance risk, though absolute rates were low.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧪 Testosterone and Type 2 diabetes risk in men [4] [AU • 26 Jun 2026]

https://www.endocrinologyadvisor.com/news/testosterone-levels-incident-type-2-diabetes-risk-men/
Context: Investigators analyzed MAILES study data from 1,299 men aged 35–80 without Type 2 diabetes, cancer, or testosterone treatment use.
Key point: Higher baseline testosterone was associated with lower 5-year incident Type 2 diabetes risk, with weaker association at older ages.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💊 Lilly opens pediatric oral GLP-1 study [5] [26 Jun 2026]

https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/3003217/lilly-targets-youth-diabetes-with-new-oral-glp-1-trial-expanding-its-glp-1-footprint/
Context: Eli Lilly listed a Phase 3, randomized, open-label study in patients aged 10 to under 18 with Type 2 diabetes.
Key point: The trial will compare once-daily oral orforglipron with once-weekly dulaglutide for glycemic control, safety, and pharmacokinetics.
Implication: Signals pipeline investment and modality expansion.

🦴 Organon and Henlius launch denosumab biosimilars [6] [CA • 23 Jun 2026]

https://www.organon.com/canada-en/
Context: Organon Canada and Shanghai Henlius Biotech launched BILDYOS (denosumab 60 mg/1 mL) and TUZEMTY (denosumab 120 mg/1.7 mL).
Key point: The products are biosimilars to PROLIA and XGEVA and are available in Canada for all reference-product indications.
Implication: Introduces competition that may affect pricing and formulary access.

📋 Entera Bio gets FDA feedback on EB613 Phase 3 [7] [US • 23 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/23/3315992/0/en/positive-fda-feedback-on-phase-3-brings-entera-bio-s-oral-osteoporosis-pill-one-step-closer-to-market.html
Context: Entera Bio’s EB613 is an oral PTH(1-34) tablet in development for postmenopausal osteoporosis.
Key point: FDA feedback supported a single randomized, double-blind, placebo-controlled Phase 3 study of about 750 women, using 12-month total hip BMD as the primary endpoint.
Implication: May influence prescriber choice and payer reviews pending full data.

🔬 Light-based imaging for thyroid cancer diagnosis [8] [US • 25 Jun 2026]

https://medicalxpress.com/news/2026-06-based-imaging-thyroid-cancer-diagnosis.html
Context: Houston Methodist researchers reported second harmonic generation microscopy findings in the Journal of Biomedical Optics.
Key point: The light-based method evaluates collagen signatures that may help distinguish papillary thyroid cancer from benign thyroid tissue.
Implication: Access programs may expand screening, initiation, and follow-up at scale.

Why it matters

Oral peptide and GLP-1 development is expanding across diabetes, obesity, osteoporosis, and pediatric populations.
Biosimilar launches in Canada may increase treatment options for osteoporosis and oncology-related bone indications.
Observational safety signals around GLP-1 therapies underscore the need for monitoring as use broadens.
Diagnostics innovation in thyroid cancer could reduce unnecessary surgery if larger validation studies support performance.
Several updates are pre-approval or pre-clinical, so clinical and regulatory impact depends on future data.

📚 View the full Endocrinology archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Endocrinology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is LyGenesis studying with Breakthrough T1D funding?

LyGenesis is supporting pre-clinical research into immune tolerance after allogeneic pancreatic islet transplantation in Type 1 diabetes. The work is tied to Dr. Eric Lagasse’s thymus program. [1]

What is VOQUEZNA being tested for in Phathom’s pHalcon-EoE-201 trial?

VOQUEZNA (vonoprazan) is being studied as an investigational oral, non-steroidal treatment for eosinophilic esophagitis in adults. The 12-week double-blind portion has completed enrollment. [2]

What did the Reuters GLP-1 report find?

Reuters reported an EHR-based observational analysis linking long-term GLP-1 use in Type 2 diabetes with higher smell and taste disturbance risk. Absolute event rates were low. [3]

What is Lilly comparing oral orforglipron against?

Eli Lilly’s Phase 3 pediatric Type 2 diabetes study compares once-daily oral orforglipron with once-weekly dulaglutide. The trial is open-label and focused on efficacy, safety, and pharmacokinetics. [5]

Which denosumab biosimilars launched in Canada?

Organon Canada and Henlius launched BILDYOS, a biosimilar to PROLIA, and TUZEMTY, a biosimilar to XGEVA. Both are available for all reference-product indications in Canada. [6]

What did FDA feedback mean for Entera Bio’s EB613?

Entera Bio said FDA feedback supported its registrational Phase 3 protocol for EB613 in postmenopausal osteoporosis. The proposed study uses total hip bone mineral density at 12 months as the primary endpoint. [7]

Entities / Keywords

LyGenesis: thymus program, Dr. Eric Lagasse, Breakthrough T1D, pancreatic islet transplantation, Type 1 diabetes, immune tolerance
Phathom Pharmaceuticals: VOQUEZNA, vonoprazan, pHalcon-EoE-201, eosinophilic esophagitis, EoE, PCAB
GLP-1 therapies: semaglutide, diabetes, smell disturbance, taste disturbance, EHR analysis, JAMA Otolaryngology
MAILES study: testosterone, incident Type 2 diabetes, men, Southern Adelaide Diabetes and Endocrine Service
Eli Lilly: orforglipron, LY3502970, dulaglutide, LY2189265, pediatric Type 2 diabetes, oral GLP-1
Organon Canada, Henlius: BILDYOS, TUZEMTY, denosumab, PROLIA, XGEVA, biosimilars, osteoporosis, oncology bone events
Entera Bio: EB613, oral PTH(1-34), oral teriparatide, postmenopausal osteoporosis, total hip BMD, N-Tab platform
Houston Methodist: second harmonic generation microscopy, SHG, papillary thyroid cancer, collagen signatures, thyroid nodules